$28.07▲ 0.28 (1.01%)
Real-time prices · US MarketsConsistently beats earnings estimates (4/4 quarters).
weak profitability metrics drag quality score.
Quality
5
Health
7
Growth
5.9
Valuation
5.9
Sentiment
5.2
Analyst Target
$28.61
▲ +1.9% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
36.9×
price-to-earnings
Forward P/E
9.7×
next 12 months est.
Market Cap
$160.0B
market capitalization
Div Yield
6.13%
dividend yield
Profit Margin
6.8%
net profit margin
Gross Margin
74.7%
revenue minus COGS
ROE
5.0%
return on equity
Beta
0.28
vs S&P 500
52-Week Range
$24 — $29
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Pfizer, Inc. right now?
Pfizer, Inc.'s Q·Score is 5.8/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Consistently beats earnings estimates (4/4 quarters). Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for PFE?
The consensus price target for PFE is $28.61, based on ratings from 26 Wall Street analysts. This is 1.9% above the current price of $28.07. Price targets are forward-looking estimates and not guarantees of future performance.
Is PFE overvalued or undervalued?
Pfizer, Inc. (PFE) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 9.7×.
When does Pfizer, Inc. report its next earnings?
Pfizer, Inc.'s next earnings report is expected on approximately November 3, 2026.
What is Pfizer, Inc.'s profit margin?
Pfizer, Inc. has a net profit margin of 6.8%, which is positive but relatively thin. Its gross margin stands at 74.7%, indicating a high-margin business model.
What is PFE's dividend yield?
Pfizer, Inc. currently offers a dividend yield of 6.13%, which is considered a high-yield dividend, above the historical S&P 500 average. Dividend yields can change based on price movements and company payout decisions.
Is Pfizer, Inc.'s revenue growing?
Pfizer, Inc. is reporting modest revenue growth of 2.6%.
How much debt does Pfizer, Inc. have?
Pfizer, Inc. has a debt-to-equity ratio of 0.74×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.27×, suggesting it should be monitored for near-term liquidity.
Compare PFE with any stock